LRK-4189
Microsatellite Stable (MSS) Colorectal Cancer
PreclinicalActive
Key Facts
Indication
Microsatellite Stable (MSS) Colorectal Cancer
Phase
Preclinical
Status
Active
Company
About Larkspur Biosciences
Larkspur Biosciences is a private, preclinical-stage biotech leveraging targeted protein degradation (TPD) to tackle adaptive resistance in cancer. The company's platform targets 'fitness genes'—proteins essential for tumor survival under stress—to unleash multiple anti-tumor mechanisms. Led by a seasoned team with deep experience in drug discovery and development from Novartis and GSK, and founded by renowned scientists like Lewis Cantley, Larkspur is advancing its lead candidate, LRK-4189, for difficult-to-treat cancers. The company is positioned in the high-potential but competitive TPD field, aiming to address significant unmet needs in oncology.
View full company profile